While targeting MRE11 presents therapeutic opportunities, it also poses challenges. The systemic inhibition of MRE11 could affect normal cells, leading to toxicity and adverse effects due to impaired DNA repair in healthy tissues. Additionally, cancer cells might develop resistance to MRE11 inhibitors, necessitating combination strategies or alternative approaches to overcome these limitations.
